TG Therapeutics' stock rose 15% since my November buy recommendation, driven by Briumvi's strong performance and strategic ...
Cybin (NYSE American: CYBN) (NEO: CYBN) , a neuropsychiatry platform company, announced its first strategic partnership agreement (“SPA”) with Segal Trials as part of its multinational pivotal Phase 3 ...
Studies conducted in mice have shown that the COVID-19 vaccine being developed by researchers at the University of São ...
Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...
ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant ...
“Most vaccines are based on attenuated or inactivated viruses, but our next-generation strategy enables us to prioritize not just safety and efficacy but also plasticity in the formulation so that the ...
Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...
Ukrainian President Volodymyr Zelenskyy will personally attend the World Economic Forum in Davos, held from January 20-24. US ...
Iconovo deal aims to identify the deal product properties concerning particle size, stability, and device compatibility.
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...
BOSTON, MA / ACCESSWIRE / / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it has ...